Drug intelligence / Profile preview

bendamustine + ofatumumab

Development stage: Unknown
Lead developer: Jenapharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Bendamustine + ofatumumab is a combination therapy regimen consisting of bendamustine, a bifunctional alkylating agent with unique cytotoxicity properties, and ofatumumab, an anti-CD20 monoclonal antibody. Bendamustine causes DNA damage through alkylation and cross-linking, while ofatumumab binds to CD20 on B lymphocytes to induce complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This combination has been studied for the treatment of various B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and indolent B-cell non-Hodgkin lymphoma.

Brand names: ArzerraTreandaBendekaBelrapzo
Other names: ofatumumab + bendamustine

Targets

CD20 (B-lymphocyte antigen CD20)DNA

Beyond the preview

Go deeper on bendamustine + ofatumumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bendamustine + ofatumumab.

Explore the full profile